Celgene Corp. (NASDAQ: CELG)and bluebird bio (NASDAQ: BLUE)are frenemies. They're working togetheron a game-changing gene therapy for multiple myeloma, but they're also on a collision course in beta thalassemia, a common genetic disease.
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться